1-(氯甲基)-4-(2-甲基丙基)苯 | 60736-79-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(氯甲基)-4-(2-甲基丙基)苯
• 英文名称: 4-isobutylbenzyl chloride
• 英文别名: 1-(Chloromethyl)-4-isobutylbenzene；1-(Chloromethyl)-4-(2-methylpropyl)benzene
• CAS: 60736-79-0
• 化学式: C₁₁H₁₅Cl
• mdl: MFCD11190946
• 分子量: 182.693
• InChiKey: RVQOLTBRWHPYTM-UHFFFAOYSA-N

物化性质

• 沸点：
  123-124 °C(Press: 15 Torr)
• 密度：
  0.996±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-(氯甲基)-4-(2-甲基丙基)苯 在 cobalt tetracarbonyl anion sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以76%的产率得到异丁芬酸
  参考文献：
  名称：

  Rao, B. Nageswara; Adapa, Srinivas R.; Pardhasaradhi, M., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1988, vol. 27, # 1-12, p. 84 - 85

  摘要：

  DOI：
• 作为产物：
  描述：

  异丁基苯 在 氯化锌 盐酸 、 paraformaldehyde 作用下， 以 溶剂黄146 为溶剂， 生成 1-(氯甲基)-4-(2-甲基丙基)苯
  参考文献：
  名称：

  Phenylalkanoic compounds and therapeutic use thereof

  摘要：

  化合物I的新型苯基烷酸类化合物的公式为##STR1##其中R.sub.1和R.sub.2分别独立地代表氢或含有1至8个碳原子的烷基，以及这些化合物及其盐，苯基烷酸类化合物的治疗用途，或其药理安全盐用于治疗炎症性疾病、咳嗽状态、疼痛症状和发热性疾病，以及含有苯基烷酸类化合物或药理安全盐的药物组合物，其中包括载体和可选的辅料或添加剂。

  公开号：

  US04381313A1

文献信息

• Quantitative relations between structure and activation of fibrinolysis in selected series of arylaliphatic acids
  作者：Miroslav Kuchař、Bohumila Brunová、Václav Rejholc、Magda Jelínková、Jiří Holubek、Oldřich Němeček

  DOI：10.1135/cccc19840122

  日期：——

  The paper describes the reaction of arylacetones IX with triethyl phosphonoacetate, producing esters of 4-aryl-3-methyl-2-butenoic acid, X, and 4-aryl-3-methyl-3-butenoic acid, X'. Their hydrolysis gave a mixture of the isomeric acids I and I', whose composition was investigated by ¹H NMR spectra. Also prepared were 3-methyl-3-phenyl-2-propenoic acids, II, 2-aryl-2-hydroxypropanoic acids, IV, and substituted α-benzyloxyphenylacetic acids, V. These acids, along with aryloxoaliphatic acids III, were investigated for efficacy in activation of fibrinolysis. The lipophilicites of the acids studied were determined either through the partition coefficients (acids Ia and IIa), using a system n-octanol-water (pH 3.5) or by partition chromatography. The experimental values of log Pwere compared with those calculated from the fragmental constants f and the parameters π. With the acids V the decrease in lipophilicity was similar to that observed with arylalkoxyaliphatic acids. With the acids, I, I' and II the fibrinolytic capacity was linearly proportional to lipophilicity. Although we evaluated fibrinolytic capacity of mixtures of the acids I and I', the linear relation was in agreement with that derived previously for a group of arylaliphatic acids. The presence of a functional group on the connecting chain in the acids III and IV had a negative effect on the fibrinolytic capacity. The decrease in fibrinolytic capacity might be due the functional groups being capable of forming hydrogen bonds.

  这篇论文描述了芳基醋酮IX与三乙基磷酸乙酯反应，生成4-芳基-3-甲基-2-丁烯酸酯X和4-芳基-3-甲基-3-丁烯酸酯X'。它们的水解产生了异构酸I和I'的混合物，其组成通过¹H NMR谱进行了研究。还制备了3-甲基-3-苯基-2-丙烯酸II，2-芳基-2-羟基丙酸IV和取代的α-苄氧基苯乙酸V。这些酸，连同芳基氧代脂肪酸III，被研究其在激活纤溶作用中的功效。所研究的酸的亲脂性通过分配系数（酸Ia和IIa）或通过分配色谱法在正辛醇-水（pH 3.5）体系中确定。实验值log P与从片段常数f和参数π计算得到的值进行了比较。对于酸V，亲脂性的降低类似于观察到的芳基氧代脂肪酸。对于酸I, I'和II，纤溶能力与亲脂性成正比。尽管我们评估了酸I和I'的混合物的纤溶能力，但线性关系与先前得出的一组芳基脂肪酸的结果一致。酸III和IV中连接链上的功能基团对纤溶能力有负面影响。纤溶能力的降低可能是由于功能基团能够形成氢键。
• Indole derivatives and their use for testosterone
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05212320A1

  公开（公告）日：1993-05-18

  Indole derivatives of the formula ##STR1## and pharmaceutical compositions thereof. They are useful for treating or preventing testosterone 5-alpha-reductase-mediated diseases, such as alopecia, acnes and prostatism.

  该公式的吲哚衍生物及其药物组合物。它们可用于治疗或预防睾酮5α-还原酶介导的疾病，如脱发、粉刺和前列腺增生。
• 4-(1-Benzoylindol-3-yl)butyric Acids and FK143: Novel Nonsteroidal Inhibitors of Steroid 5.ALPHA.-Reductase. (II).
  作者：Kozo SAWADA、Satoshi OKADA、Patrick GOLDEN、Natsuko KAYAKIRI、Yuki SAWADA、Masashi HASHIMOTO、Hirokazu TANAKA

  DOI：10.1248/cpb.47.481

  日期：——

  A novel series of indolebutyric acids with varying benzoyl substituents were synthesized to develop nonsteroidal inhibitors of steroid 5α-reductase. We previously reported the discovery of a novel nonsteroidal 5α-reductase inhibitor, FR119680, which had an IC50 value of 5.0 nM against the rat prostatic enzyme. However, this compound was not strongly active against the human prostatic enzyme. By further study of the structure-activity relationships we succeeded in producing the strongly active compound, FK143, 4-[3-[3-[bis(4-isobutylphenyl)-methylamino]benzoyl]-1H-indol-1-yl]butyric acid, with an IC50 value of 1.9 nM against the human enzyme. FK143 also has in vivo inhibitory activity against the castrated young rat model and it should therefore be an extremely useful agent for the treatment of benign prostatic hyperplasia.

  合成了一系列新的吲哚丁酸，其苯甲酰取代基各不相同，以开发非甾体类的类固醇5α-还原酶抑制剂。我们之前报道了一种新型非甾体5α-还原酶抑制剂FR119680，其在大鼠前列腺酶上的IC50值为5.0 nM。然而，该化合物对人前列腺酶的活性并不强。通过进一步研究结构-活性关系，我们成功合成了强效化合物FK143，4-[3-[3-[双(4-异丁基苯)-甲胺]苯甲酰]-1H-吲哚-1-基]丁酸，其对人酶的IC50值为1.9 nM。FK143在去势年轻大鼠模型中也表现出体内抑制活性，因此它应该是治疗良性前列腺增生的极为有用的药物。
• Antiinflammatory substituted phenylacetic acids
  申请人：SPOFA, United Pharmaceutical Works

  公开号：US04221919A1

  公开（公告）日：1980-09-09

  Antiinflammatory substituted phenylacetic acids of low toxicity are prepared by reaction of a salt of an alkyl 3 chloro-4-hydroxyphenylacetate with a substituted benzyl halide in the presence of an inert organic solvent at elevated temperatures.

  低毒性的抗炎替代苯乙酸是通过在惰性有机溶剂存在下，在高温下反应烷基3氯-4-羟基苯乙酸盐和取代苯甲基卤代物制备的。
• Fungal cell wall synthesis gene
  申请人：——

  公开号：US20040038239A1

  公开（公告）日：2004-02-26

  A reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered. Further, genes conferring resistance to the above compounds were identified and methods of screening for compounds that inhibit the activity of the proteins encoded by these genes were developed. Therefore, through the novel compounds, the present invention showed that antifungal agents having a novel mechanism, i.e. inhibiting the process that transports GPI-anchored proteins to the cell wall, could be achieved.

  构建了一个反映将GPI锚定蛋白转运到细胞壁的运输过程的报告系统，并发现了抑制该过程的化合物。此外，还鉴定了赋予对上述化合物抗性的基因，并开发了筛选抑制这些基因编码的蛋白质活性的化合物的方法。因此，通过新型化合物，本发明展示了可以实现具有新型机制（即抑制将GPI锚定蛋白转运到细胞壁的过程）的抗真菌剂。